tiprankstipranks
Advertisement
Advertisement

XERS Stock Latest News

Xeris Pharmaceuticals Signals Profitable Growth Acceleration
Company AnnouncementsXeris Pharmaceuticals Signals Profitable Growth Acceleration
19d ago
XERS
Xeris Biopharma reports Q1 EPS 1c, consensus 0c
PremiumThe Fly
Xeris Biopharma reports Q1 EPS 1c, consensus 0c
20d ago
XERS
Xeris Biopharma Announces Board Transition as Director Retires
PremiumCompany Announcements
Xeris Biopharma Announces Board Transition as Director Retires
1M ago
8K
XERS
Xeris Pharmaceuticals Earnings Call Highlights Rapid Growth
PremiumCompany Announcements
Xeris Pharmaceuticals Earnings Call Highlights Rapid Growth
3M ago
XERS
Nasus Approaches Key Data Readout That Could Reshape the Multi Billion Dollar Epinephrine Market (NYSE: NSRX)
PremiumTipRanks Newswire
Nasus Approaches Key Data Readout That Could Reshape the Multi Billion Dollar Epinephrine Market (NYSE: NSRX)
3M ago
NSRX
XERS
Xeris Biopharma reports Q4 revenue 6c vs. (3c) last year
PremiumThe FlyXeris Biopharma reports Q4 revenue 6c vs. (3c) last year
3M ago
XERS
Xeris Biopharma sees FY26 revenue $375M-$390M, consensus $368M
Premium
The Fly
Xeris Biopharma sees FY26 revenue $375M-$390M, consensus $368M
3M ago
XERS
Xeris Pharmaceuticals (XERS) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Xeris Pharmaceuticals (XERS) Q4 Earnings Cheat Sheet
3M ago
XERS
Xeris Biopharma subsidiaries file Recorlev patent infringement lawsuit
PremiumThe Fly
Xeris Biopharma subsidiaries file Recorlev patent infringement lawsuit
3M ago
XERS
TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI
PremiumMarket News
TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI
3M ago
COF
VIR
Xeris Biopharma: Strong 2025 Outperformance and Underappreciated Multiyear Growth Drive Buy Rating
PremiumRatings
Xeris Biopharma: Strong 2025 Outperformance and Underappreciated Multiyear Growth Drive Buy Rating
5M ago
XERS
Xeris Biopharma initiated with an Overweight at Barclays
PremiumThe Fly
Xeris Biopharma initiated with an Overweight at Barclays
6M ago
XERS
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121
PremiumCompany AnnouncementsXeris Pharmaceuticals Secures Patent Allowance for XP-8121
6M ago
8K
XERS
Xeris Biopharma issued notice of allowance from USPTO for XP-8121
Premium
The Fly
Xeris Biopharma issued notice of allowance from USPTO for XP-8121
6M ago
XERS
Xeris Biopharma price target raised to $8 from $6 at Piper Sandler
Premium
The Fly
Xeris Biopharma price target raised to $8 from $6 at Piper Sandler
7M ago
XERS
Xeris Pharmaceuticals: Strong Growth Potential and First Profitable Quarter Drive Buy Rating
PremiumRatings
Xeris Pharmaceuticals: Strong Growth Potential and First Profitable Quarter Drive Buy Rating
7M ago
XERS
Xeris Biopharma Reports Strong Q3 2025 Financial Results
PremiumCompany Announcements
Xeris Biopharma Reports Strong Q3 2025 Financial Results
7M ago
XERS
Xeris Biopharma Reports Record Revenue Growth in Earnings Call
PremiumCompany Announcements
Xeris Biopharma Reports Record Revenue Growth in Earnings Call
7M ago
XERS
Xeris Biopharma reports Q3 EPS 0c, consensus 0c
PremiumThe Fly
Xeris Biopharma reports Q3 EPS 0c, consensus 0c
7M ago
XERS
Xeris Biopharma price target raised to $18 from $8 at Oppenheimer
PremiumThe FlyXeris Biopharma price target raised to $18 from $8 at Oppenheimer
7M ago
XERS
American Regent launches Gvoke VialDx
Premium
The Fly
American Regent launches Gvoke VialDx
9M ago
XERS
Xeris Biopharma announces Orange Book listing of U.S. patent for Recorlev
Premium
The Fly
Xeris Biopharma announces Orange Book listing of U.S. patent for Recorlev
9M ago
XERS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >